Progestogens for preterm birth prevention: A systematic review and meta-analysis

Obstetrics and Gynecology

Volumn 120, Issue 4, 2012, Pages 897-907

  Likis, Frances E ^a   Edwards, Digna R Velez ^b   Andrews, Jeffrey C ^b   Woodworth, Alison L ^b   Jerome, Rebecca N ^b   Fonnesbeck, Christopher J ^b   McKoy, J Nikki ^b   Hartmann, Katherine E ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

BAYES THEOREM; CERVICAL LENGTH MEASUREMENT; DRUG EFFICACY; HUMAN; MATERNAL WELFARE; META ANALYSIS; MULTIPLE PREGNANCY; NEWBORN DEATH; NEWBORN MORTALITY; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 84866983740     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182699a15     Document Type: Review

References (46)

1. Use of progesterone to reduce preterm birth. Committee Opinion No. 419. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008;112:963-5.
2. Use of progesterone to reduce preterm birth. Committee Opinion. American College of Obstetricians and Gynecologists. Obstet Gynecol 2003;102:1115-6.
3. Henderson ZT, Power ML, Berghella V, Lackritz EM, Schulkin J. Attitudes and practices regarding use of progesterone to prevent preterm births. Am J Perinatol 2009;26:529-36.
4. Likis FE, Andrews JC, Woodworth AL, Velez Edwards DR, Jerome RN, Fonnesbeck CJ, et al. Progestogens for prevention of preterm birth. Rockville (MD): Agency for Healthcare Research and Quality; 2012.
5. Gelman A, Carlin J, Stern H, Rubin DB. Bayesian data analysis. Boca Raton (FL): Chapman and Hall/CRC; 2004.
6. Sutton A, Abrams K. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001;10:277-303.
7. Patil A, Huard D, Fonnesbeck C. Bayesian stochastic modelling in python. J Stat Softw 2010;35:1-81.
8. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17-hydroxyprogesterone caproate. N Engl J Med 2003; 348:2379-85.
9. Majhi P, Bagga R, Kalra J, Sharma M. Intravaginal use of natural micronised progesterone to prevent pre-term birth: A randomised trial in India. J Obstet Gynaecol 2009;29:493-8.
10. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: Primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:687-96.
11. Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009;104:40-3.
12. Glover MM, McKenna DS, Downing CM, Smith DB, Croom CS, Sonek JD. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol 2011;28:377-81.
13. Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJHM, et al. 17-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstet Gynecol 2011; 118:513-20.
14. Combs CA, Garite T, Maurel K, Das A, Porto M. 17-hydroxyprogesterone caproate for twin pregnancy: A double-blind, randomized clinical trial. Am J Obstet Gynecol 2011;204: 221.e1-8.
15. Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): A randomised, doubleblind, placebo-controlled study and meta-analysis. Lancet 2009;373:2034-40.
16. Briery CM, Veillon EW, Klauser CK, Martin RW, Chauhan SP, Magann EF, et al. Progesterone does not prevent preterm births in women with twins. South Med J 2009;102:900-4.
17. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357: 454-61.
18. Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY, et al. Prevention of preterm birth in triplets using 17-hydroxyprogesterone caproate: A randomized controlled trial. Obstet Gynecol 2009;113:285-92.
19. Combs CA, Garite T, Maurel K, Das A, Porto M. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: A double-blind, randomized clinical trial. Am J Obstet Gynecol 2010;203:248.e1-9.
20. Facchinetti F, Dante G, Venturini P, Paganelli S, Volpe A. 17-hydroxy-progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. Am J Perinatol 2008;25:503-6.
21. Breart G, Lanfranchi M, Chavigny C, Rumeau-Rouquette C, Sureau C. A comparative study of the efficiency of hydroxyprogesterone caproate and of chlormadinone acetate in the prevention of premature labor. Int J Gynaecol Obstet 1979; 16:381-4.
22. Erny R, Pigne A, Prouvost C, Gamerre M, Malet C, Serment H, et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol 1986;154:525-9.
23. Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: A randomised controlled trial. Aust N Z J Obstet Gynaecol 2008;48: 58-63.
24. Noblot G, Audra P, Dargent D, Faguer B, Mellier G. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1991;40: 203-9.
25. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: Effects of 17-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:453.e1-4.
26. Fuchs F, Stakemann G. Treatment of threatened premature labor with large doses of progesterone. Am J Obstet Gynecol 1960;79:172-6.
27. Chawanpaiboon S, Pimol K, Sirisomboon R. Comparison of success rate of nifedipine, progesterone, and bed rest for inhibiting uterine contraction in threatened preterm labor. J Obstet Gynaecol Res 2011;37:787-91.
28. Sharami SH, Zahiri Z, Shakiba M, Milani F. Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: A randomized placebo-controlled double-blind trial. Int J Fertil Steril 2010;4:45-50.
29. Ibrahim M, Mohamed Ramy AR, Younis MAF. Progesterone supplementation for prevention of preterm labor: A randomized controlled trial. Middle East Fertil Soc J 2010; 15:39-41.
30. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462-9.
31. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: A multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18-31.
32. Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, et al. Prevention of premature labor by 17-hydroxyprogesterone caproate. Am J Obstet Gynecol 1985; 151:574-7.
33. Hobel CJ, Ross MG, Bemis RL, Bragonier JR, Nessim S, Sandhu M, et al. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high-risk women. Am J Obstet Gynecol 1994;170:54-62.
34. Johnson JW, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975;293:675-80.
35. Cetingoz E, Cam C, Sakalli M, Karateke A, Celik C, Sancak A. Progesterone effects on preterm birth in high-risk pregnancies: A randomized placebo-controlled trial. Arch Gynecol Obstet 2011;283:423-9.
36. Keeler SM, Kiefer D, Rochon M, Quinones JN, Novetsky AP, Rust O. A randomized trial of cerclage vs 17-hydroxyprogesterone caproate for treatment of short cervix. J Perinat Med 2009;37:473-9.
37. Berghella V, Figueroa D, Szychowski JM, Owen J, Hankins GD, Iams JD, et al. 17-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010;202: 351.e1-6.
38. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188: 419-24.
39. Hauth JC, Gilstrap LC 3rd, Brekken AL, Hauth JM. The effect of 17-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 1983;146:187-90.
40. Corrado F, Dugo C, Cannata ML, Di Bartolo M, Scilipoti A, Carlo Stella N. A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. Eur J Obstet Gynecol Reprod Biol 2002;100:196-8.
41. Briery CM, Veillon EW, Klauser CK, Martin RW, Magann EF, Chauhan SP, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 2011;204:54.e1-5.
42. Trotter A, Maier L, Grill HJ, Kohn T, Heckmann M, Pohlandt F. Effects of postnatal estradiol and progesterone replacement in extremely preterm infants. J Clin Endocrinol Metab 1999; 84:4531-5.
43. Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R. Clinical characteristics of women prescribed 17-hydroxyprogesterone caproate in the community setting. Am J Obstet Gynecol 2007;197:262.e1-4.
44. Gruneiro-Papendieck L, Prieto L, Chiesa A, Bengolea S, Bossi G, Bergada C. Neonatal screening program for congenital adrenal hyperplasia: Adjustments to the recall protocol. Horm Res 2001;55:271-7.
45. Brancazio LR, Murtha AP, Heine RP. Prevention of recurrent preterm delivery by 17-hydroxyprogesterone caproate. N Engl J Med 2003;349:1087-8; author reply 1087-8.
46. Iams JD. Was the preterm birth rate in the placebo group too high in the Meis MFMU Network trial of 17-OHPC? Am J Obstet Gynecol 2010;202:409-10.